This study helps bridge some information gaps in our previous study by highlighting the advanced biological effects of these analogs in triple negative breast cancer, namely the analysis of cell-cycle moderators, expanded EGFR-pathway protein analysis, apoptosis screening, molecular dynamic interactions, and ADMET factors for drug compatibility. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.